 This study examined the effectiveness of different treatments for intrahepatic recurrent hepatocellular carcinoma, RHCC, after hepatic resection, HX. It found that the prognostic factors for overall survival, OS, and disease-free survival, DFS, included the duration of disease-free interval, DFI, less than 1.5 years, type of Retreatment, Transarterial Chemoembolization or Transcatheter Arterial Infusion, TAI, age, younger than 65 years old, and perioperative red blood cell transfusions. Additionally, the repeat HX group had the best outcomes compared with the other two groups. This article was authored by Michinori Matsumoto, Katsuhiko Yanaga, Hiroaki Shiba, and others.